The FDA Could Help Address Financial Toxicity During the Approval Process

Shereen Stutz, RPH
Published: Saturday, Sep 21, 2019
Cancer is among the costliest medical conditions to treat in the United States,1 causing many patients to experience “financial toxicity.” This term is often used to describe how out-of-pocket costs can cause financial distress to patients.

There is also financial toxicity from the perspective of companies that offer insurance to employees. Partly because of the high cost of medications, employers have to pay more for their employee health plans, which in turn increases the amount employees must be charged for coverage.

... to read the full story

To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication